印度以121项新的药物标准推出最新药典,促进全球健康监督和认识。 India launches updated pharmacopoeia with 121 new drug standards, boosting global health oversight and recognition.

第10版《2026年印度药典》以121本新专著推出,使总数达到3 340本,提高了抗结核、抗糖尿病、抗癌症药物、铁补充剂和血液成分的标准。 The Indian Pharmacopoeia 2026, the 10th edition, was launched with 121 new monographs, bringing the total to 3,340, enhancing standards for anti-tubercular, anti-diabetic, anti-cancer drugs, iron supplements, and blood components. 它标志着印度日益增强的全球影响力,其标准现已在全球南部19个国家得到认可。 It marks India’s rising global influence, with its standards now recognized in 19 countries of the global south. 印度的药物监测报告从2025年全球第123次上升到第8次,反映出通过印度药物监测方案加强了药物安全监测。 India’s pharmacovigilance reporting rose from 123rd to 8th globally by 2025, reflecting improved drug safety monitoring through the Pharmacovigilance Programme of India. 最新情况报告加强了监管监督,支持了国家卫生方案和全球制药供应链。 The update strengthens regulatory oversight and supports national health programs and the global pharmaceutical supply chain.